Log in

Relevant bibliographies by topics / Allogeneic grafts

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Allogeneic grafts'

Author: Grafiati

Published: 28 June 2021

Last updated: 13 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Allogeneic grafts.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Allogeneic grafts"

1

Widner, Håkan, and Patrik Brundin. "Sequential Intracerebral Transplantation of Allogeneic and Syngeneic Fetal Dopamine-Rich Neuronal Tissue in Adult Rats: Will the First Graft be Rejected?" Cell Transplantation 2, no. 4 (July 1993): 307–17. http://dx.doi.org/10.1177/096368979300200413.

Full text

Abstract:

The immune response against intracerebral grafts of allogeneic fetal dopamine-rich tissue was assessed in adult rats. Sprague-Dawley rats, now outbred, but originating from an inbred stock, were given unilateral 6-hydroxy-dopamine lesions of the mesostriatal pathway, and grafted intrastriatally with mechanically dissociated ventral mesencephalic tissue (embryonic day 13-15) obtained from an inbred Lewis strain. Graft survival was assessed by functional recovery of amphetamine-induced rotational behavior on four different occasions postsurgery, and histologically using catecholamine histofluorescence and tyrosine hydroxylase immunohistochemistry. The following groups were analysed: long-term survival of a single allogeneic graft; survival of a first allogeneic graft with a syngeneic second graft; survival of a first allograft combined with a second allogeneic graft; the survival of bilateral allogeneic grafts following a subsequent orthotopic allogeneic skin graft. Evidence for recipient immunization was obtained using an indirect fluorescent antibody detection technique, Simonsen's Spleen Index (S I) test. Viable grafts, giving rise to behavioral compensation, were present after 40 wk in rats from all groups. The “first” allograft always displayed good survival and function, even following a second intracerebral allograft. However, five of nine “second” allogeneic intracerebral grafts survived poorly. In contrast, all secondary syngeneic grafts survived well. Following the application of a subsequent orthotopic allogeneic skin graft in a subgroup of rats, there was a significantly lower survival of grafted dopamine neurons in the “first” graft.

APA, Harvard, Vancouver, ISO, and other styles

2

Zhao, Shanshan, Dai Shi, Chen Su, Wen Jiang, Chao Zhang, Ting Liang, and Guihua Hou. "IL-27Rα: A Novel Molecular Imaging Marker for Allograft Rejection." International Journal of Molecular Sciences 21, no. 4 (February 15, 2020): 1315. http://dx.doi.org/10.3390/ijms21041315.

Full text

Abstract:

Non-invasively monitoring allogeneic graft rejection with a specific marker is of great importance for prognosis of patients. Recently, data revealed that IL-27Rα was up-regulated in alloreactive CD4+ T cells and participated in inflammatory diseases. Here, we evaluated whether IL-27Rα could be used in monitoring allogeneic graft rejection both in vitro and in vivo. Allogeneic (C57BL/6 donor to BALB/c recipient) and syngeneic (BALB/c both as donor and recipient) skin grafted mouse models were established. The expression of IL-27Rα in grafts was detected. The radio-probe, 125I-anti-IL-27Rα mAb, was prepared. Dynamic whole-body phosphor-autoradiography, ex vivo biodistribution and immunofluorescence staining were performed. The results showed that the highest expression of IL-27Rα was detected in allogeneic grafts on day 10 post transplantation (top period of allorejection). 125I-anti-IL-27Rα mAb was successfully prepared with higher specificity and affinity. Whole-body phosphor-autoradiography showed higher radioactivity accumulation in allogeneic grafts than syngeneic grafts on day 10. The uptake of 125I-anti-IL-27Rα mAb in allogeneic grafts could be almost totally blocked by pre-injection with excess unlabeled anti-IL-27Rα mAb. Interestingly, we found that 125I-anti-IL-27Rα mAb accumulated in allogeneic grafts, along with weaker inflammation earlier on day 6. The high uptake of 125I-anti-IL-27Rα mAb was correlated with the higher infiltrated IL-27Rα positive cells (CD3+/CD68+) in allogeneic grafts. In conclusion, IL-27Rα may be a novel molecular imaging marker to predict allorejection.

APA, Harvard, Vancouver, ISO, and other styles

3

Hyc, Anna, Jacek Malejczyk, Anna Osiecka, and Stanislaw Moskalewski. "Immunological Response against Allogeneic Chondrocytes Transplanted into Joint Surface Defects in Rats." Cell Transplantation 6, no. 2 (March 1997): 119–24. http://dx.doi.org/10.1177/096368979700600205.

Full text

Abstract:

Rat chondrocytes isolated from the articular–epiphyseal cartilage complex were transplanted into defects prepared in articular cartilage and subchondral bone. Transplants were taken for examination after 3 and 8 wk. Cartilage formed by syngeneic chondrocytes did not evoke formation of infiltrations. Contrary to that, in the vicinity of cartilage produced by allogeneic chondrocytes numerous infiltrating cells were present and cartilage resorption could be observed. Cyclosporine-A (CsA) treatment of recipients of allogeneic chondrocytes only partially suppressed accumulation of infiltrating cells and matrix resorption. Antichondrocyte immune response of chondrocyte graft recipients was studied by evaluation of spleen mononuclear cells (SMC) stimulation in mixed splenocytechondrocyte cultures and by evaluation of antichondrocyte cytotoxic antibodies. No difference in stimulation of SMC from intact rats by syngeneic and allogeneic chondrocytes was observed. Stimulation by allogeneic chondrocytes was slightly but significantly higher in recipients of syngeneic grafts. SMC of allogenic chondrocyte recipients were strongly stimulated by allogeneic chondrocytes. This response was absent in recipients treated with CsA. Spontaneous antichondrocyte cytotoxic antibody activity was detected in intact rats and in recipients of syngeneic grafts. In recipients of allogeneic chondrocytes the antibody response against allogeneic chondrocytes was raised but was statistically not significant owing to the considerable variation in the level of spontaneously occurring antichondrocyte antibodies.

APA, Harvard, Vancouver, ISO, and other styles

4

Mahan, KT, and HJ Hillstrom. "Bone grafting in foot and ankle surgery. A review of 300 cases." Journal of the American Podiatric Medical Association 88, no. 3 (March 1, 1998): 109–18. http://dx.doi.org/10.7547/87507315-88-3-109.

Full text

Abstract:

Three hundred foot and ankle bone grafts were reviewed in three separate series of 100 consecutive grafts from two institutions. The series represent a period from 1977 to 1990 and demonstrate treatment patterns that varied over time and between institutions in indications, graft material, and perioperative management. Over 42% of the 300 grafts were for calcaneal osteotomies; most were Evans calcaneal osteotomies. Over 72% of the grafts were allogeneic bone-bank bone, which performed well in calcaneal osteotomies and for packing of defects. Upon review of the incidence of bone complications, no significant differences were observed between surgical procedures that used autogenous versus allogeneic grafts. However, four out of six failures of first metatarsal repair were with allogeneic bone. There was a significant difference in complication rates for the major indications for bone-graft surgery. Nonunions and arthrodeses resulted in higher complication rates than expected, whereas calcaneal osteotomies resulted in a lower complication rate than expected.

APA, Harvard, Vancouver, ISO, and other styles

5

Wallowy, Phillip, and Andreas Dorow. "Lateral Augmentation of the Maxilla and Mandible Using Framework Technique With Allogeneic Bone Grafts." Journal of Oral Implantology 38, no. 6 (December 1, 2012): 661–67. http://dx.doi.org/10.1563/aaid-joi-d-11-00073.

Full text

Abstract:

This study aimed to evaluate the effectiveness of lateral ridge augmentation in 36 patients with severely atrophic alveolar ridge using allogeneic bone grafts in a framework technique. A thinned allogeneic cortical graft was screwed to the alveolar ridge, leaving a hollow space that was filled with particulated allogeneic cortical bone. Thirty-six patients who received surgical lateral block augmentation using allogeneic bone grafts were involved in this study. Implants were placed in a second session after a mean time of 6.3 months. The surgical technique and the reasons for failure of surgery in three patients are described. Additionally, properties of allogeneic bone grafts are reviewed. In 33 patients, dental implants were successfully installed and continued to be well maintained at the last follow-up (91.7% success). In three patients, dental implants could not be installed (8.3% failure) as the graft was lost because of wound dehiscence; however, repeat surgery was successfully carried out in all three. The use of allogeneic bone grafts in lateral ridge augmentation of the maxilla and mandible showed successful clinical results. It seems to be a reliable material for reconstructing a severely atrophic alveolar ridge. It presents a good alternative to autogenous bone regarding augmentation because it offers good ossification, less morbidity, unlimited availability and shorter duration of surgery, and lower costs.

APA, Harvard, Vancouver, ISO, and other styles

6

Mellonig, James T. "Autogenous and Allogeneic Bone Grafts in Periodontal Therapy." Critical Reviews in Oral Biology & Medicine 3, no. 4 (July 1992): 333–52. http://dx.doi.org/10.1177/10454411920030040201.

Full text

Abstract:

This article is limited to a review of bone autografts and allografts, as used in periodontal therapy. The various graft materials are discussed with respect to case reports, controlled clinical trials, and human histology. Other reviewed areas are wound healing with periodontal bone grafts, tissue banking and freeze-dried bone allografts, and the use of bone grafts in guided tissue regeneration.

APA, Harvard, Vancouver, ISO, and other styles

7

Monje, Alberto, Michael A. Pikos, Hsun-Liang Chan, Fernando Suarez, Jordi Gargallo-Albiol, Federico Hernández-Alfaro, Pablo Galindo-Moreno, and Hom-Lay Wang. "On the Feasibility of Utilizing Allogeneic Bone Blocks for Atrophic Maxillary Augmentation." BioMed Research International 2014 (2014): 1–12. http://dx.doi.org/10.1155/2014/814578.

Full text

Abstract:

Purpose. This systematic review was aimed at assessing the feasibility by means of survival rate, histologic analysis, and causes of failure of allogeneic block grafts for augmenting the atrophic maxilla.Material and Methods. A literature search was conducted by one reviewer in several databases. Articles were included in this systematic review if they were human clinical trials in which outcomes of allogeneic bone block grafts were studied by means of survival rate. In addition other factors were extracted in order to assess their influence upon graft failure.Results. Fifteen articles fulfilled the inclusion criteria and subsequently were analyzed in this systematic review. A total of 361 block grafts could be followed 4 to 9 months after the surgery, of which 9 (2.4%) failed within 1 month to 2 months after the surgery. Additionally, a weighed mean 4.79 mm (95% CI: 4.51–5.08) horizontal bone gain was computed from 119 grafted sites in 5 studies. Regarding implant cumulative survival rate, the weighed mean was 96.9% (95% CI: 92.8–98.7%), computed from 228 implants over a mean follow-up period of 23.9 months. Histologic analysis showed that allogeneic block grafts behave differently in the early stages of healing when compared to autogenous block grafts.Conclusion. Atrophied maxillary reconstruction with allogeneic bone block grafts represents a reliable option as shown by low block graft failure rate, minimal resorption, and high implant survival rate.

APA, Harvard, Vancouver, ISO, and other styles

8

Aydin, Cemalettin, Volkan Ince, Emrah Otan, Sami Akbulut, Cemalettin Koc, Cuneyt Kayaalp, and Sezai Yilmaz. "Storage of Allogeneic Vascular Grafts: Experience From a High-Volume Liver Transplant Institute." International Surgery 98, no. 2 (May 1, 2013): 170–74. http://dx.doi.org/10.9738/intsurg-d-12-00035.1.

Full text

Abstract:

Abstract Allogeneic vascular grafts are often required for vascular reconstruction during living donor liver transplantation. Such grafts are obtained prior to use, making storage conditions a critical issue for maintaining the integrity of the tissue to ensure a successful transplantation. This study describes an optimized storage protocol currently in use at a high-volume liver transplant center. Twenty-nine allogeneic vascular graft tissues obtained during cardiovascular surgery or from cadaveric donors were stored respectively in sterile 50 mL of Ringer lactate solution, without any preservation solutions or antimicrobials, at −22°C for a maximum of 3 months. Prior to use in vascular reconstruction, grafts were thawed in 0.9% NaCl solution at 37°C, and 1 × 0.5-cm2 tissue samples were collected for microbial culturing and viral serology. ABO compatibility was not performed for any patients receiving vascular grafts. During this prospective study, all 29 allogeneic vascular grafts were used for back-table vascular reconstruction in living donor liver transplantation procedures. A total of 16 grafts were from the saphenous vein, 10 were from the iliac vein, and 3 were from the iliac artery. Bacterial growth was not detected in any tissue samples taken from the stored grafts. No vascular graft-related complications occurred during the 5 months of follow-up. The successful vascular reconstructions achieved with all 29 study grafts demonstrate that the simple, inexpensive storage method described herein is feasible and safe. Randomized, controlled studies should be carried out to further optimize and standardize the technique.

APA, Harvard, Vancouver, ISO, and other styles

9

Glass, Bertram, Lutz Uharek, Matthias Zeis, Peter Dreger, Helmut Löffler, Jörg Steinmann, and Norbert Schmitz. "Allogeneic Peripheral Blood Progenitor Cell Transplantation in a Murine Model: Evidence for an Improved Graft-Versus-Leukemia Effect." Blood 90, no. 4 (August 15, 1997): 1694–700. http://dx.doi.org/10.1182/blood.v90.4.1694.

Full text

Abstract:

Abstract Peripheral blood progenitor cells (PBPCs) are increasingly being used to replace bone marrow cells (BMCs) as a source of hematopoietic stem cells also in the field of allogeneic transplantation. Whereas it is well known that PBPC grafts and BM differ significantly in progenitor cell content and lymphocyte dose, the clinical consequences of these differences with respect to engraftment, graft-versus-host disease (GVHD), and the graft-versus-leukemia (GVL) effect are more difficult to assess. We present a murine model that allows us to evaluate engraftment, GVHD, and GVL effect of allogeneic PBPC transplantation (PBPCT). Balb/c mice (H-2d) served as recipients. Donors were major histocompatibility complex-matched DBA/2 mice or syngeneic Balb/c mice, respectively. Experiments with increasing numbers of BMCs or Filgastrim-mobilized PBPCs showed that the number of progenitor cells in the graft was correlated with the probability to engraft, irrespective of the graft type. With identically high cell numbers transferred (1 × 109 nucleated cells/kg body weight [BW]), the mortality rates due to GVHD (25%) were about the same after allogeneic BM transplantation (BMT) and allogeneic PBPCT, although PBPC grafts contained four times more CD3+ T cells as compared with BM grafts (6.2 × 108v 1.4 × 108/kg BW). For investigation of GVL activity, Balb/c recipients were injected with syngeneic cells of the B-lymphocytic leukemia cell line A20 2 days before transplantation. After total body irradiation to a dose of 7.5 Gy, 1 × 109/kg BW Balb/c PBPCs, DBA BMCs, or DBA PBPCs were infused. The relapse rates observed were 80% after syngeneic PBPCT (n = 22), 60% after allogeneic BMT (n = 23), and 34% after allogeneic PBPCT (n = 26) (allogeneic BMT v PBPCT, P = .032). We conclude that transplantation of allogeneic PBPCs instead of BM may enhance the GVL effect without an increase of GVHD.

APA, Harvard, Vancouver, ISO, and other styles

10

Glass, Bertram, Lutz Uharek, Matthias Zeis, Peter Dreger, Helmut Löffler, Jörg Steinmann, and Norbert Schmitz. "Allogeneic Peripheral Blood Progenitor Cell Transplantation in a Murine Model: Evidence for an Improved Graft-Versus-Leukemia Effect." Blood 90, no. 4 (August 15, 1997): 1694–700. http://dx.doi.org/10.1182/blood.v90.4.1694.1694_1694_1700.

Full text

Abstract:

Peripheral blood progenitor cells (PBPCs) are increasingly being used to replace bone marrow cells (BMCs) as a source of hematopoietic stem cells also in the field of allogeneic transplantation. Whereas it is well known that PBPC grafts and BM differ significantly in progenitor cell content and lymphocyte dose, the clinical consequences of these differences with respect to engraftment, graft-versus-host disease (GVHD), and the graft-versus-leukemia (GVL) effect are more difficult to assess. We present a murine model that allows us to evaluate engraftment, GVHD, and GVL effect of allogeneic PBPC transplantation (PBPCT). Balb/c mice (H-2d) served as recipients. Donors were major histocompatibility complex-matched DBA/2 mice or syngeneic Balb/c mice, respectively. Experiments with increasing numbers of BMCs or Filgastrim-mobilized PBPCs showed that the number of progenitor cells in the graft was correlated with the probability to engraft, irrespective of the graft type. With identically high cell numbers transferred (1 × 109 nucleated cells/kg body weight [BW]), the mortality rates due to GVHD (25%) were about the same after allogeneic BM transplantation (BMT) and allogeneic PBPCT, although PBPC grafts contained four times more CD3+ T cells as compared with BM grafts (6.2 × 108v 1.4 × 108/kg BW). For investigation of GVL activity, Balb/c recipients were injected with syngeneic cells of the B-lymphocytic leukemia cell line A20 2 days before transplantation. After total body irradiation to a dose of 7.5 Gy, 1 × 109/kg BW Balb/c PBPCs, DBA BMCs, or DBA PBPCs were infused. The relapse rates observed were 80% after syngeneic PBPCT (n = 22), 60% after allogeneic BMT (n = 23), and 34% after allogeneic PBPCT (n = 26) (allogeneic BMT v PBPCT, P = .032). We conclude that transplantation of allogeneic PBPCs instead of BM may enhance the GVL effect without an increase of GVHD.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Allogeneic grafts"

1

陸梅 and Mei Lu. "Allogeneic bone grafts mixed with basic fibroblast growth factor: a cellular and molecular study." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2002. http://hub.hku.hk/bib/B29866340.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Torchia, Mark G. "Thymic inoculation does not result in development of tolerance to allogeneic thyroid grafts in the outbred rabbit." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1997. http://www.collectionscanada.ca/obj/s4/f2/dsk2/ftp04/mq23531.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Wang, Xiao Nong. "Quantitative analysis of alloreactive T cells in allogeneic stem cell transplantation." Thesis, University of Newcastle Upon Tyne, 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.362419.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Laylor, Ruthline Maria. "Characterisation of host versus graft responses following allogeneic stem cell transplantation." Thesis, Imperial College London, 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.417391.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Carlens, Stefan. "Leukaemic relapse after allogeneic haematopoietic stem cell transplantation and the use of the graft-versus-leukaemia effect /." Stockholm, 2000. http://diss.kib.ki.se/2000/91-628-4310-9/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Jaksch, Marie. "Molecular monitoring of acute graft-versus-host disease after allogeneic stem cell transplantation /." Stockholm, 2004. http://diss.kib.ki.se/2004/91-7349-987-0/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Niimi, Masanori. "An investigation to determine the ability of allogeneic resting B cells to induce specific unresponsiveness in vivo." Thesis, University of Oxford, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.244813.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Avent, Kassi. "Molecular Analysis of Oligoclonal T cells Associated with Graft-Versus-Host Disease Following Allogeneic Stem-cell Transplantation." VCU Scholars Compass, 2012. http://scholarscompass.vcu.edu/etd/2712.

Full text

Abstract:

The goal of hematopoietic stem cell transplantation (HSCT) is to induce graft-versus-tumor effect (GVT), which is the recognition of and response against tumor- associated antigens (TAAs) by donor immune cells to clear the recipient of residual tumor. A complication of HSCT as a treatment for hematologic malignancies is graft-versus-host disease (GVHD), which is the recognition and reactivity of donor immune cells against healthy tissues. As of now, the differentiation between GVHD and GVT effects has been a hindrance to the development of effective therapies against GVHD. Certain T cell clones may induce both GVHD and GVT effects, making targeted therapy of GVHD difficult. This project was aimed to uncover differences at a molecular level of the T cell recognition site that exist between patients with GVHD and those with GVHD-free survival following allogeneic HSCT. We found that there are inherent differences in the T cell receptor at a molecular level between patients experiencing GVHD and those that are GVHD-free, suggesting the ability of T cells to distinguish tumor cells from self cells. In addition, the intention was to reveal differences in proportions of engrafted donor T cells and stem cells and the effects of these proportions on the severity, outcome, and prognosis of GVHD. We additionally found that a lower proportion of stem cells to T cells was associated with the trend of GVHD, while a higher frequency of T cells engrafted into host may indicate resistance to treatment and a poor prognosis. These data suggest that allogeneic HSCT may be improved by optimizing the proportion of T cells to stem cells in the transplant as well as developing targeted therapy against GVHD-associated T cell clones while rescuing GVT-associated T cell clones.

APA, Harvard, Vancouver, ISO, and other styles

9

Cullup, Hannah. "An investigation of interleukin-1 in graft versus host disease following allogeneic bone marrow transplantation." Thesis, University of Newcastle Upon Tyne, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.247827.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Berrie, Jennifer. "DISTINCT T CELL CLONES ARE ASSOCIATED WITH GRAFT-VERSUS-HOST DISEASE (GVHD), AND POTENTIALLY GRAFT-VERSUS-TUMOR (GVT), RESPONSES FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION." VCU Scholars Compass, 2011. http://scholarscompass.vcu.edu/etd/2450.

Full text

Abstract:

In patients undergoing hematopoietic stem cell transplantation (HSCT) with HLA-identical donors, genetic polymorphisms result in a mismatch between donors and recipients in their minor histocompatibility antigens (mHAgs), and tumors may also express tumor-associated antigens (TAA) that may not be abundantly present in the donors. Donor T cells can recognize such mHAgs and TAAs as foreign antigens and generate an objective response against hematologic malignancies in a graft-versus-tumor (GVT) effect. However, a major side effect of HSCT occurs when donor T cells are alloreactive against the recipients’ normal cells, leading to graft-versus-host disease (GVHD). The ability to identify T cell clones that are exclusively involved in the GVT or GVHD responses remains elusive. In this study, we looked at clonally-driven CD3+ T cells in patients with hematologic malignancies prior to and after transplantation. We identified Vbeta families of increased expression involved in GVHD or GVT responses, with Vbetas 4, 11, and 23 being associated with GVHD, Vbetas 9, 16, and 20 being associated with GVT, and Vbetas 2, 3, 7, 8, 12, 15, and 17 being involved in GVHD and/or GVT. We were also able to identify some of the Vbeta families that were increased in the peripheral blood at the site of GVHD. Furthermore, one of our twelve patients had donor lymphocyte infusions (DLIs) for treatment of relapse, from which we were able to observe oligoclonal T cells that emerged at the time of post-DLI remission and re-establishment of GVHD.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Allogeneic grafts"

1

Wong, Paul Kim Chiu. Reconstruction of large acetabular defects using allogeneic and autogeneic morselized bone grafts: An in vivo & mathematical study using a canine uncemented total hip arthroplasty (THA) model. Ottawa: National Library of Canada, 1993.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Barrett/Jiang. Allogeneic Immunotherapy for Malignant Diseases (Basic and Clinical Oncology). Informa Healthcare, 2000.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Provan, Drew, Trevor Baglin, Inderjeet Dokal, Johannes de Vos, and Hassan Al-Sader. Haematopoietic stem cell transplantation. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199683307.003.0009.

Full text

Abstract:

Haemopoietic stem cell transplantation (SCT) - Indications for haemopoietic SCT - Allogeneic SCT - Autologous STC - Investigations for BMT/PBSCT - Pretransplant investigation of donors - Bone marrow harvesting - Peripheral blood stem cell mobilization and harvesting - Microbiological screening for stem cell cryopreservation - Stem cell transplant conditioning regimens - Infusion of cryopreserved stem cells - Infusion of fresh non-cryopreserved stem cells - Blood product support for SCT - Graft-versus-host disease (GvHD) prophylaxis - Acute GvHD - Chronic GvHD - Veno-occlusive disease (syn. sinusoidal obstruction syndrome) - Invasive fungal infections and antifungal therapy - CMV prophylaxis and treatment - Post-transplant vaccination programme and foreign travel - Longer term effect post-transplant - Treatment of relapse post-allogeneic SCT - Discharge and follow-up

APA, Harvard, Vancouver, ISO, and other styles

4

Wingard, John R. Introduction. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199938568.003.0300.

Full text

Abstract:

This chapter starts by explaining that the goal of allogeneic stem cell transplantation is the establishment of donor hematopoiesis and immunity in the recipient to treat an antecedent marrow failure disorder or to achieve a graft-versus-cancer effect to treat a neoplastic disease. The goal of autologous hematopoietic stem cell transplant (HSCT) is very different from allogeneic HSCT. In autologous HSCT, the goal of the graft is simpler: it is to rescue the myelotoxic effects of high-dose chemotherapy. Neutropenia is shorter, cellular immunodeficiency is less profound, and immune reconstitution is quicker. Infectious exposures before transplant play an important role after transplant. Although an infection may be effectively treated and under good control before transplant, reactivation may occur after transplant. The search for risk factors that can identify individuals at greatest risk for various types of infection has led to the identification of neutropenia, lymphopenia (or low CD4+ cell counts), low levels of immunoglobulin, and GVHD, prior infection by organisms that may persist in the recipient or donor, and a number of other factors in certain situations. The chapter concludes that one of the biggest challenges is distinguishing infection from some other noninfectious etiology of a syndrome.

APA, Harvard, Vancouver, ISO, and other styles

5

Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation: Models in Discovery and Translation. Elsevier Science & Technology Books, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Socie, Gerard, Bruce R. Blazar, and Robert Zeiser. Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation: Models in Discovery and Translation. Elsevier Science & Technology, 2018.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Retter, Andrew. Management of the bone marrow transplant recipient in ICU. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0375.

Full text

Abstract:

Bone marrow transplants are an exciting and rapidly evolving area of haematology providing life-saving therapy to many patients and the number performed annually is increasing. Transplants are generally not considered as first line therapy due to their inherent toxicity and high rate of complications. The patients tend to have more heavily pre-treated disease with it attendant toxicities and a decreased physiological reserve. Admission rates vary between series from 15 to 30%. It is increasingly important that intensivists are aware of the basic principles of bone marrow transplantation and its’ possible morbidities. There are two types of transplant autologous transplants, where the patient’s own stem cells are returned to them and transplants from a donor. Only allogeneic transplants are associated with graft-versus-host disease. Allograft recipients also require immunosuppression to prevent transplant rejection. It is essential that this immunosuppression is continued when patients are admitted to intensive care. Transplant patients are always severely immunocompromised and prone to prolonged periods of neutropenia. They routinely receive antiviral, antifungal, and antibacterial prophylaxis, which must be continued on their admission. They remain vulnerable to unusual infections presenting in an atypical fashion. It is essential to have both a very low clinical threshold of suspicion for infection and detailed local protocols established to guide empirical antimicrobial therapy. Although traditionally poor, the prognosis is slowly improving.

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Allogeneic grafts"

1

Alho, A., E. O. Karaharju, O. Korkala, E. Laasonen, T. Holmström, and G. P. Andersen. "Allogeneic Osteoarticular Grafts About the Knee." In Bone Transplantation, 327–28. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-83571-1_71.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Komender, Janusz, Hanna Malczewska, and Andrzej Komender. "Preserved, Allogeneic Bone Grafts in Orthopaedic Reconstructions." In Orthopaedic Allograft Surgery, 39–44. Vienna: Springer Vienna, 1996. http://dx.doi.org/10.1007/978-3-7091-6885-1_4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Noga, Stephen J. "Engineering Hematopoietic Grafts Using Elutriation and Positive Cell Selection to Reduce GVHD." In Advances in Allogeneic Hematopoietic Stem Cell Transplantation, 311–30. Boston, MA: Springer US, 1999. http://dx.doi.org/10.1007/978-1-4615-4987-1_14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Speck, B., A. Gratwohl, B. Osterwalder, C. Nissen, and E. Signer. "Experience with 100 Allogeneic Marrow Grafts Using Cyclosporin-A (CYA) for Prophylaxis Against GVHD." In 11th Annual meeting of the EBMT, 126. Berlin, Heidelberg: Springer Berlin Heidelberg, 1985. http://dx.doi.org/10.1007/978-3-662-40457-7_100.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Melville, James C., Huy Q. Tran, Jonathan W. Shum, Ramzey Tursun, and Robert E. Marx. "Reconstruction of Post-Traumatic Maxillary Ridges Using a Radial Forearm Free Flap and Allogeneic Tissue-Engineered Bone Grafts." In Regenerative Medicine and Plastic Surgery, 349–55. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-19958-6_30.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Jagasia, Madan, and Steven Pavletic. "Chronic Graft-Versus-Host Disease." In Allogeneic Stem Cell Transplantation, 577–95. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-478-0_33.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Cutler, Corey, Vincent T. Ho, and Joseph H. Antin. "Acute Graft Versus Host Disease: Prophylaxis." In Allogeneic Stem Cell Transplantation, 565–76. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-478-0_32.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Wolff, Steven N. "Second Hematopoietic Stem Cell Transplantation for the Treatment of Graft Failure, Graft Rejection, or Relapse." In Allogeneic Stem Cell Transplantation, 311–24. Totowa, NJ: Humana Press, 2003. http://dx.doi.org/10.1007/978-1-59259-333-0_20.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Sun, Kai, William J. Murphy, and Lisbeth A. Welniak. "In Vivo Models for the Study of Graft-vs-Host Disease and Graft-vs-Tumor Effects." In Allogeneic Stem Cell Transplantation, 373–86. Totowa, NJ: Humana Press, 2003. http://dx.doi.org/10.1007/978-1-59259-333-0_24.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Goldstein, Steven C., Sophie D. Stein, and David L. Porter. "Treatment of Acute Graft-vs-Host Disease." In Allogeneic Stem Cell Transplantation, 747–65. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-478-0_42.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Allogeneic grafts"

1

Thyagarajan, Bharat, Bruce Lindgren, Saonli Basu, Sriharsha Nagaraj, Myron Gross, Daniel Wesidorf, and Mukta Arora. "Abstract 4656: DNA repair polymorphisms as predictors of Graft-versus-Host Disease after allogeneic hematopoietic cell transplants." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-4656.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

CARON, C., J. P. JOUET, J. HIMPENS, P. HIVES, H. GRUSON, and J. GOUDEMAND. "MODERATE DECREASE OF FACTOR VII AND PROTEIN C WITHOUT OCCURRENCE OF HEPATIC VENO-OCCLUSIVE DISEASE AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION IN 18 PATIENTS TREATED WITH LOW DOSE HEPARIN." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644337.

Full text

Abstract:

Decrease of factor VII (F VII) and protein C (PC) has been said to allow an early detection of hepatic veno-occlusive disease (VOD) (VILMER, Path. Biol. 1986, 34 : 79), that represents a serious complication of bone marrow transplantation (BMT). In this purpose, F VII (activity) and PC (antigen) have been measured in 18 patients (aged 9 to 45 yr- m : 26 yr) who underwent allogeneic bone marrow graft for chronic myelogenous leukemia (9 cases), acute lymphocytic leukemia (7 cases) acute myelogenous leukemia (2 cases). All patients received as preparation for BMT total body irradiation (mean dose = 10 Gy) along with cyclophosphamide (120 mg/Kg). All were given low dose heparin (100 UI/Kg/24 hr) from days -7 to +30. None of the patients developed VOD but graft-versus-host disease occurred in 13 out of them between days 18 and 52. Moreover, coagulation studies performed from days 1 to 28 detected a moderate decrease of F VII and PC (maximum on day 11). These parameters were normalized on day 28. The level of the other vitamin K-dependent factors was not significantly changed.So the moderate decrease of F VII and PC found in the post-graft period was not associated with hepatic VOD. However, as none of the patients developed this complication, these results do not exclude that a major decrease of these parameters could serve as an early diagnosis of VOD. On the other hand, a prophylactic effect of low dose heparin cannot be ruled out.

APA, Harvard, Vancouver, ISO, and other styles

3

Gowdy, Kymberly, Julia L. Nugent, Laurie D. Snyder, Tereza Martinu, and Scott M. Palmer. "LPS Potentiates Th17 And Th2 Mediated Chronic Pulmonary Graft-Versus-Host Disease (GVHD) After Allogeneic Bone Marrow Transplant (BMT)." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a1088.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Martinu, Tereza, Julia L. Nugent, Kymberly Gowdy, Jesse Sun, Matthew A. Lyes, Christine V. Kinnier, Francine L. Kelly, et al. "Critical Role Of CCL2 (MCP-1) In The Development Of Pulmonary Graft-Versus-Host Disease After Murine Allogeneic Bone Marrow Transplant." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a5126.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Kavouridou, Christina, Karin Mellgren, Anders Lindblad, Per Gustafsson, and Karsten Koetz. "Multiple breath washout can facilitate the diagnosis of lung graft-versus-host disease in children after allogeneic hematopoietic stem cell transplantation." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.oa4554.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Kim, Seo Yeon, Hyewon Lee, Hyoeun Shim, Hyeon-Seok Eom, and Sun-Young Kong. "Abstract 2536: Post-transplantation NK cell is a useful predictor of graft-versus-host-disease in allogeneic hematopoietic stem cell transplantation." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-2536.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Leigh, Nicholas D., Kathleen M. Kokolus, Jason W.-L. Eng, Jingxin Qiu, George L. Chen, Philip L. McCarthy, Xuefang Cao, and Elizabeth A. Repasky. "Abstract B43: The degree of adrenergic stress signaling regulates the severity of graft versus host disease following allogeneic hematopoietic cell transplantation." In Abstracts: AACR Special Conference: Tumor Immunology and Immunotherapy: A New Chapter; December 1-4, 2014; Orlando, FL. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/2326-6074.tumimm14-b43.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Allogeneic grafts"

1

Meyer, Anthony A. Efficacy of Allogenic Cultured Keratinocyte Grafts for Burn Wounds. Fort Belvoir, VA: Defense Technical Information Center, June 1993. http://dx.doi.org/10.21236/ada267262.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!